GAM
TELO icon

Gotham Asset Management’s Telomir Pharmaceuticals TELO Stock Holding History

Gotham Asset Management’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,770
Closed -$229K – 1676
2024
Q4 		$229K Buy
+6,770
New +$31.9K ﹤0.01% 1333

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gotham Asset Management's TELO Position: Q1 2025 in Review

Gotham Asset Management sold out of Telomir Pharmaceuticals (TELO) in Q1 2025, closing a stake of 6,770 shares — an estimated $229K sold.

Gotham Asset Management first reported a position in TELO in Q4 2024 and held it in 1 quarter. The position peaked at $229K in Q4 2024. 42 funds tracked by Wall St. Rank hold TELO as of Q1 2025.

  • Gotham Asset Management reported no remaining Telomir Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Gotham Asset Management sold 6,770 Telomir Pharmaceuticals shares in Q1 2025, an estimated $229K.
  • Gotham Asset Management first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Gotham Asset Management's Telomir Pharmaceuticals position peaked at $229K in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2025.

Based on Gotham Asset Management's 13F filing for Q1 2025, filed 15 May 2025.